Newsmeme!
Discover News you didn't know existed
Immunocompromised
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Cepheid Announces CE IVD Release Of First On-Demand Test For Van A/van B Genes Most Associated With Hospital-Acquired ...
Published October 8, 2008, 3:07 am, Medical News Today
Cepheid (Nasdaq: CPHD) announced the release of Xpert(TM) vanA/vanB as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The test delivers rapid detection of vanA and/or vanB genes, the genes most commonly associated with vancomycin-resistant enterococci (VRE) -- one of the more serious healthcare acquired infections (HAIs) worldwide.
Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired ...
Published October 7, 2008, 4:00 am, PR Newswire via Yahoo! Finance
Cepheid today announced the release of Xpert vanA/vanB as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The test delivers rapid detection of vanA and/or vanB genes, the genes most commonly associated with vancomycin-resistant enterococci -- one of the more serious healthcare acquired infections worldwide.
Genentech Issues Dear Healthcare Provider Letter Regarding A Reported Case Of PML In A Raptiva Patient
Published October 4, 2008, 3:08 am, Medical News Today
Genentech, Inc. (NYSE: DNA) announced that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a case of progressive multifocal leukoencephalopathy (PML) in a 70-year old patient who had received Raptiva® (efalizumab) for more than four years for treatment of chronic plaque psoriasis. The company will work with the U.S.
Severe Adverse Event Reported In Raptiva Patient
Published October 3, 2008, 7:07 am, Medical News Today
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Genentech Inc. has reported a case of progressive multifocal leukoencephalopathy (PML) in a 70-year old patient who had received Raptiva (efalizumab) for more than four years of treatment of chronic plaque psoriasis. Genentech markets Raptiva in the United States.
Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient
Published October 2, 2008, 3:26 pm, Centre Daily Times
Genentech, Inc. (NYSE:DNA) announced today that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a case of progressive multifocal leukoencephalopathy (PML) in a 70-year old patient who had received Raptiva(R) (efalizumab) for more than four years for treatment of chronic plaque psoriasis. The company will work with the U.S. Food and Drug Administration ...
Severe Adverse Event Reported in Raptiva(R) Patient
Published October 2, 2008, 3:11 pm, PR Newswire via Yahoo! Finance
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced
Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient
Published October 2, 2008, 3:09 pm, Finanzen.net
Genentech, Inc. (NYSE:DNA) announced today that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a ...
Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient
Published October 2, 2008, 3:03 pm, Business Wire via Yahoo! Finance
SOUTH SAN FRANCISCO, Calif.----Genentech, Inc. announced today that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a case of progressive multifocal leukoencephalopathy in a 70-year old patient who had received Raptiva® for more than four years for treatment of chronic plaque psoriasis.
Methylgene Receives Clinical Trial Approval from Health Canada for its Proprietary Product Candidate MGCD290 for ...
Published October 2, 2008, 4:30 am, Marketwire via Yahoo! Finance
MethylGene Inc. today announced that Health Canada has approved the Company's clinical trial application for MGCD290, a fungal Hos2 histone deacetylase inhibitor to be used in combination with azoles for the treatment of fungal infections.
ViraCor Laboratories Launches Comprehensive Testing for Fungal Infections
Published October 1, 2008, 9:01 am, Centre Daily Times
ViraCor Laboratories, a specialty molecular diagnostic reference laboratory that provides same day turnaround for laboratory tests, today announced the launch of a comprehensive mycology, or fungus, testing service that will allow the company to quickly detect potentially deadly fungal infections in patients. Fast diagnosis of fungal infections can significantly improve patient outcomes and ...
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |